Compare NOMD & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NOMD | HROW |
|---|---|---|
| Founded | 2014 | 1998 |
| Country | United Kingdom | United States |
| Employees | N/A | 373 |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | 2015 | N/A |
| Metric | NOMD | HROW |
|---|---|---|
| Price | $11.33 | $45.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $12.50 | ★ $69.86 |
| AVG Volume (30 Days) | ★ 1.3M | 855.5K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | ★ 7.11% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $31.62 |
| Revenue Next Year | $1.45 | $50.77 |
| P/E Ratio | $8.38 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.99 | $28.54 |
| 52 Week High | $18.33 | $54.98 |
| Indicator | NOMD | HROW |
|---|---|---|
| Relative Strength Index (RSI) | 65.52 | 65.44 |
| Support Level | $11.04 | $44.30 |
| Resistance Level | $12.36 | $51.01 |
| Average True Range (ATR) | 0.34 | 2.24 |
| MACD | 0.08 | 0.32 |
| Stochastic Oscillator | 82.68 | 78.83 |
Nomad Foods Ltd is a packaged foods company that is involved in the business of manufacturing and distributing branded frozen foods in Western Europe. The company manufactures and markets frozen food products such as fish, vegetables, poultry, Ice Cream, and ready meals like pizza. It sells its products through large grocery retailers under the brand Birds Eye in the United Kingdom and Ireland, Findus in Italy, France, Spain, and Iglo in Germany and other continental markets. The company operates through a single segment being Frozen. The majority of the revenue is generated from the United Kingdom.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.